A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

被引：3
|
作者：
Lakhani, Nehal J.
Rasco, Drew W.
Tolcher, Anthony W.
Huang, Yingjie
Ji, Jiao
Wang, Hengbang
Dong, Qi
Men, Lichuang
O'Rourke, Timothy J.
Chandana, Sreenivasa R.
Amaya, Alex
Cole, Yvette
Kaiser, Brianne
Mays, Theresa A.
Patnaik, Amita
Papadopoulos, Kyriakos P.
Yang, Dajun
Zhai, Yifan
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[3] Ascentage Pharma Grp Inc, Rockville, MD USA
[4] Suzhou Ascentage Pharma Inc, Suzhou, Peoples R China
[5] Suzhou Ascentage Pharma Inc, Suzhou, Peoples R China
[6] Canc & Hem Ctr West Michigan, Grand Rapids, MI USA
[7] Western Michigan Canc Ctr, Kalamazoo, MI USA
[8] START Ctr Canc Care, San Antonio, TX USA
[9] START Midwest Canc Hematol Centers Western Michig, Grand Rapids, MI USA
[10] South Texas Accelerated Res Therapeut START Ctr C, San Antonio, TX USA
[11] START, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2594
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Combined inhibition of Bcl-2 and MCL-1 in small cell lung cancer (SCLC) is most effective in tumors with low Bcl-xL expression
    Drapkin, Benjamin J.
    Sanghavi, Sneha
    Myers, David T.
    Zhong, Jun
    Phat, Sarah
    Wang, Youzhen
    Halilovic, Ensar
    Golji, Javad
    Farago, Anna
    Morris, Erick
    Dyson, Nicholas J.
    CANCER RESEARCH, 2019, 79 (13)
  • [22] BCL-2, BCL-XL, AND PP32/PHAPI IN RESECTED NON-SMALL CELL LUNG CANCER PATIENTS
    Schmidt, Lars Henning
    Kuemmel, Andreas
    Martin, Schuler M.
    Biesterfeld, Stefan
    Faldum, Andreas
    Sebastian, Martin
    Taube, Christian
    Buhl, Roland
    Wiewrodt, Rainer
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3479 - 3479
  • [23] Bcl-2, Bcl-xl, and pp32/PHAPI in Resected Non-Small-Cell Lung Cancer Patients
    Schmidt, L. H.
    Kuemmel, A.
    Schuler, M.
    Biesterfeld, S.
    Faldum, A.
    Taube, C.
    Buhl, R.
    Mueller-Tidow, C.
    Wiewrodt, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [24] Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
    Gandhi, Leena
    Camidge, D. Ross
    de Oliveira, Moacyr Ribeiro
    Bonomi, Philip
    Gandara, David
    Khaira, Divis
    Hann, Christine L.
    McKeegan, Evelyn M.
    Litvinovich, Elizabeth
    Hemken, Philip M.
    Dive, Caroline
    Enschede, Sari H.
    Nolan, Cathy
    Chiu, Yi-Lin
    Busman, Todd
    Xiong, Hao
    Krivoshik, Andrew P.
    Humerickhouse, Rod
    Shapiro, Geoffrey I.
    Rudin, Charles M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) : 909 - 916
  • [25] The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
    Luo, Qiu-yun
    Yang, Jing
    Di, Tian
    Xia, Zeng-fei
    Zhang, Lin
    Pan, Wen-tao
    Shi, Shan
    Yang, Li-qiong
    Sun, Jian
    Qiu, Miao-zhen
    Yang, Da-jun
    ACTA PHARMACOLOGICA SINICA, 2024, : 1082 - 1096
  • [26] PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer
    Khan, Sajid
    Cao, Lin
    Wiegand, Janet
    Zhang, Peiyi
    Zajac-Kaye, Maria
    Kaye, Frederic J.
    Zheng, Guangrong
    Zhou, Daohong
    CELLS, 2024, 13 (06)
  • [27] Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis
    Yao, Weilong
    Bai, Longchuan
    Wang, Shaomeng
    Zhai, Yifan
    Sun, Shi-Yong
    NEOPLASIA, 2022, 29
  • [28] First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
    Lakhani, Nehal J.
    Rasco, Drew
    Wang, Hengbang
    Men, Lichuang
    Liang, Eric
    Fu, Tommy
    Collins, Mary C.
    Min, Ping
    Yin, Yan
    Davids, Matthew S.
    Yang, Dajun
    Zhai, Yifan
    CLINICAL CANCER RESEARCH, 2024, 30 (03) : 506 - 521
  • [29] The balance between Bcl-2 family members governs the cellular sensitivity of small cell lung cancer to the Bcl-2/Bcl-XL antagonist, ABT-737.
    Tse, C
    Tahir, SK
    Anderson, MG
    Yang, XF
    Sarthy, A
    Morgan-Lappe, S
    Chen, J
    Ng, SC
    Fesik, S
    Rosenberg, S
    Elmore, S
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9040S - 9040S
  • [30] Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer
    Yang, J.
    Pradhan, R. S.
    Rosen, L. S.
    Graham, A. M.
    Holen, K. D.
    Xiong, H.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (06) : 680 - 684
12345